
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. is positioned for growth with its expansive product portfolio in regenerative medicine, addressing both advanced wound care and surgical applications. The company operates in an underpenetrated market, presenting significant opportunities for further expansion and additional total addressable market (TAM) beyond current offerings. Expectations for normalized operating dynamics in the second half of FY25 suggest a positive trajectory for financial performance as plans materialize, reinforcing a favorable outlook for the company's future growth.
Bears say
The financial outlook for Organogenesis Holdings Inc. appears negative due to several key factors, including anticipated lower growth for the PuraPly product line and challenges related to Medicare Part B pricing on amniotic products. The company is also facing heightened competition, with competitors potentially able to navigate regulatory hurdles more efficiently, which could hinder Organogenesis's market share gains. Additionally, the substantial investment of approximately $30 million in the ReNu program, coupled with delays in obtaining regulatory clearance, further adds to the negative sentiment surrounding the company's financial stability and future revenue expectations.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares